Publications

Reviews

Westover KD, Jänne PA, Gray NS. Progress on Covalent Inhibition of KRASG12C. Cancer Discov. 2016 Mar;6(3):233-4.

Download pdf

Müller S, Chaikuad A, Gray NS, Knapp S. The ins and outs of selective kinase inhibitor development. Nat Chem Biol. 2015 Oct 20;11(11):818-21.

Download pdf

Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, Bountra C, Brennan PE, Brown PJ, Bunnage ME, Buser-Doepner C, Campbell RM, Carter AJ, Cohen P, Copeland RA, Cravatt B, Dahlin JL, Dhanak D, Edwards AM, Frye SV, Gray N, Grimshaw CE, Hepworth D, Howe T, Huber KV, Jin J, Knapp S, Kotz JD, Kruger RG, Lowe D, Mader MM, Marsden B, Mueller-Fahrnow A, Müller S, O'Hagan RC, Overington JP, Owen DR, Rosenberg SH, Roth B, Ross R, Schapira M, Schreiber SL, Shoichet B, Sundström M, Superti-Furga G, Taunton J, Toledo-Sherman L, Walpole C, Walters MA, Willson TM, Workman P, Young RN, Zuercher WJ. The promise and peril of chemical probes. Nat Chem Biol. 2015 Jul 21;11(8):536-41. doi: 10.1038/nchembio.1867.

Download pdf

Wang J, Gray NS. SnapShot: Kinase Inhibitors II. Mol Cell. 2015 May 21;58(4):710-710.

Download pdf

Wang J, Gray NS. SnapShot: Kinase Inhibitors I. Mol Cell. 2015 May 21;58(4):708-708.

Download pdf

Zhao Z, Wu H, Wang L, Liu Y, Knapp S, Liu Q, Gray NS. Exploration of Type II Binding Mode: a Privileged Approach for Kinase Inhibitor Focused Drug Discovery? ACS Chem Biol. 2014 Apr 14.

Download pdf

Liu Q, Sabnis Y, Zhao Z, Zhang T, Buhrlage SJ, Jones LH, Gray NS. Developing irreversible inhibitors of the protein kinase cysteinome. Chem Biol. 2013 Feb 21;20(2):146-59.

 

Download pdf

Knapp S, Arruda P, Blagg J, Burley S, Drewry DH, Edwards A, Fabbro D, Gillespie P, Gray NS, Kuster B, Lackey KE, Mazzafera P, Tomkinson NC, Willson TM, Workman P, Zuercher WJ. A public-private partnership to unlock the untargeted kinome. Nat Chem Biol. 2013 Jan;9(1):3-6.

 

Download pdf

Deng X, Choi HG, Buhrlage SJ, Gray NS. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011). Expert Opin Ther Pat. 2012 Dec;22(12):1415-26.

 

Download pdf

Deng X, Gray NS. Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756). Expert Opin Ther Pat. 2012 Jun;22(6):709-13.

 

Download pdf

Haber DA, Gray NS, Baselga J.  The evolving war on cancer.  Cell. 2011 Apr 1;145(1):19-24. PMID:21458664

 

 

Download pdf

Hur W, Gray NS.  Small molecule modulators of antioxidant response pathway.  Curr Opin Chem Biol. 2011 Feb;15(1):162-73. Epub 2010 Dec 30. Review.  PMID:21195017

 

 

Download pdf


Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS.  mTOR Mediated Anti-Cancer Drug Discovery.  Drug Discov Today Ther Strateg. 2009 Summer;6(2):47-55.  PMID:20622997

 

Download pdf

Jänne PA, Gray NS, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov. 2009

 

 

Download pdf

Weisberg E, Barrett R, Liu Q, Stone R, Gray N, Griffin JD. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat 2009;12(3):81-9.

 

Download pdf

Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9(1):28-39.

 

Download pdf

Goldstein DM, Gray NS, Zarrinkar PP.  High-throughput kinase profiling as a platform for drug discovery.  Nat Rev Drug Discov 2008;7(5):391-7.

 

Download pdf

Peters EC, Gray NS. Chemical proteomics identifies unanticipated targets of clinical kinase inhibitors.  ACS Chem Biol 2007;2(10):661-4.

 

Download pdf

Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2:358-64.

 

Download pdf

Nagle A, Hur W, Gray NS. Antimitotic agents of natural origin. Curr Drug Targets 2006;7:305-26.

 

Download pdf

Li B, Liu Y, Uno T, Gray N. Creating chemical diversity to target protein kinases. Comb Chem High Throughput Screen 2004;7:453-72.

Download pdf

Warmuth M, Damoiseaux R, Liu Y, Fabbro D, Gray N. SRC family kinases: potential targets for the treatment of human cancer and leukemia. Curr Pharm Des 2003;9:2043-59.

Download pdf

Ruetz S, Fabbro D, Zimmermann J, Meyer T, Gray N. Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors. Curr Med Chem Anticancer Agents 2003;3:1-14.

Download pdf

Gray NS. Combinatorial libraries and biological discovery. Curr Opin Neurobiol 2001;11:608-14.

Download pdf

Gray NS, Detivaud L, Doerig C, Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr Med Chem 1999;6:859-75.

Download pdf